OCULAR DRUG DELIVERY SYSTEMS: A REVIEW

LAURA MACOVEI 1,3*, ALINA GHEORGHE 1,2*, SPERANTA SCHMITZER 1,2#, MARIAN BURCEA 1,2#, MATEI MOROSANU 2

1 “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021, Bucharest, Romania
2 Emergency Ophthalmology Hospital Bucharest, 1 Lahovari Square, 010464, Bucharest, Romania
3 “Carol Davila” Central Military Emergency Hospital, 010825, Bucharest, Romania

*corresponding author: alina.gheorghe.g@gmail.com
#Authors with equal contribution.

Abstract

The unique ocular route of drug administration comes with its own challenges, as novel nanotechnology based drug delivery systems and implants are being developed in order to overcome the drawbacks associated with conventional methods. Although, eye drops are convenient, safe, immediately active, patient compliant and non-invasive, the drug must be transported across several barriers, as most of the topically administered dose is lost rapidly within five to six minutes after administration due to reflux blinking and nasolacral drainage. Devices such as punctual plugs are used to prolong the retention time and increase the absorption of eye-drops, by blocking the nasolacral drainage system. Drug loaded nanoparticles have been developed in order to increase drug retention time, permeation and ocular bioavailability and intravitreal implants provide localized, controlled and sustained drug release over an extended period of time, with reduced side effects and enhanced ability to circumvent the blood retina barrier.

Keywords: ocular drug delivery systems, novel approaches, nanotechnology, implants

Introduction

The eye can be the site of many diseases (some of which sight-threatening) and taking into account it’s unique anatomy and physiology, treating these various diseases has always been a challenge for physicians and the pharmaceutical industry, especially when considering the route of drug administration. Topical eye-drops are widely used and usually the preferred type of medication administered regarding the anterior segment of the eye. However, these drugs do not usually reach the retina, vitreous or choroid, for which there are other preferred routes of drug administration, as novel technologies are being developed.

Current drug delivery systems

Eye drops

Topical instillation is the elected route of drug administration regarding the anterior part of the eye and although eye drops are useful, safe and act immediately, the drug must be transported across several barriers (tear film, cornea and conjunctiva) that protect the eye from exogenous substances and external stress [1, 2].

Most of the topically administered dose, regardless of the instilled volume, is lost rapidly within the first six minutes after administration because of the reflux blinking or nasolacral drainage. Only 20% (approximately 7 μL) is retained in the conjunctival pocket and just 1–3% actually reaches the intraocular tissue [1–4].

Various additives (such as viscosity enhancers, permeation enhancers and cyclodextrins) and ophthalmic vehicles (suspensions, emulsions and ointments) may be used to increase retention time, permeation and ocular bioavailability [1, 2].

Viscosity enhancers (such as hydroxy methyl cellulose) have been proven to enhance the preocular retention
time. Preservatives, chelating agents, bile salts and surface active agents act as permeation enhancers, by improving the corneal uptake and bioavailability of the drug [1, 5].

Cyclodextrins are agents that can encapsulate hydrophobic drug molecules in a hydrophilic aqueous solution, acting as carriers and while the lipophilic cell membrane absorbs the drug, it does not allow passage of the cyclodextrins, which were reported to produce an optimal drug bioavailability at concentration levels of less than 15% [1, 5-9].

**Emulsions**

An emulsion is an oil-in-water or water-in-oil formula that enhances the drug’s solubility, it’s precorneal resistance time and permeation across the cornea, increasing the release time and bioavailability [1, 5, 10-13]. AzaSite®, Refresh Endura® and Restasis™ are such examples [1, 5, 14-16].

Recently, Tajika et al. suggested that an emulsion based formula of [3H]-diluprednate, a prednisolone derivate, can be used for treating anterior ocular inflammation at concentration levels of 0.05%, with small amounts of the drug even reaching tissues such as vitreous, retina and choroid in rabbit eyes following not only single, as well as multiple topical drug instillation [1, 5, 17].

Liu et al. showed that azithromycin acted better as an emulsion (using lipid sources such as soybean lecithin or stearylamine as additives and carriers) when compared to an aqueous solution, with parameters such as chemical stability, precorneal retention time, drug release time and bioavailability being improved, as the pharmacokinetics of tear elimination after topical instillation shows, also in the rabbit eye [1, 5, 18].

Similarly, Shen et al. attempted to improve the bioavailability and reduce ocular irritation of flurbiprofen as an active pharmaceutical ingredient, by combining a derivate (flurbiprofen acetyl) with castor oil (a lipidic excipient) and tween-80 (a stabilizer) to form an emulsion. Aqueous humor pharmacokinetic studies were conducted after topical drop instillation in male New Zealand Albino rabbits [1, 5, 19].

Other researchers have studied the efficacy of polymers such as chitosan or hydroxypropyl methyl cellulose ether as coating agents for emulsions, as an indomethacin emulsion demonstrated better pre-conorneal residence time and bioavailability when coated by chitosan. Concentrations levels were assessed in the conjunctiva, cornea and aqueous humor following tear fluid pharmacokinetic studies conducted in rabbits following topical instillation [1, 5, 20-22].

**Ointments**

An Ophthalmic ointment is a carrier system for topical application that has demonstrated increased bioavailability and sustained drug release. These are comprised of solid and semisolid hydrocarbon molecules (paraffin) and have a melting point of 34°C, the physiological ocular temperature [1, 5, 23-27].

Fukuda et al. studied the intraocular dynamics of ophthalmic ointments based on vancomycin (an antibiotic with high activity against methicillin and cephem resistant *Staphylococcus aureus* and anaerobic and aerobic gram positive bacteria) in rabbits and demonstrated higher corneal concentration levels in eyes with induced *Bacillus subtilis* corneal infection than in the normal control group eyes, with higher than minimum growth inhibitory concentration levels regarding methicillin and cephem resistant *Staphylococcus aureus* (MRSA) maintained for as much as 240 minutes after topical administration [1, 5, 28]. The reason for the observed effect relies on breaks within the ocular barriers which seem to improve drug permeation in unhealthy eyes, as improved outcomes based on increased permeability in healthy ocular tissues are yet to be projected [1, 5, 29].

Eguchi et al. concluded 0.3% to be an adequate and effective concentration level of vancomycin for MRSA keratitis resolution after topical application of liquid paraffin and Vaseline based ointments in rabbit model eyes [1, 5, 30].

**Suspensions**

A suspension is a non-invasive topical drop drug carrier system known for its improved duration of action and drug contact time. They carry the drug as a dispersion of divided insoluble active pharmaceutical ingredients (API) in an aqueous solvent. The suspension particles are being retained in the conjunctival pocket, with duration of action being particle size dependent [1, 5, 31-33].

TobraDex®, containing both dexamethasone and tobramycin is a widely used anti-inflammatory and anti-infective suspension. Recent attempts have been made in order to reduce its viscosity by using xanthan gum to form ionic interactions with tobramycin, as bactericidal activity, tear film kinetics, tissue permeation and patient compliance all improved. Higher tissues concentrations of the active pharmaceutical ingredients, as well as higher effectiveness against *Staphylococcus aureus* and *Pseudomonas aeruginosa* were observed [1, 2, 5, 34-37].

**Novel approaches**

In order to overcome drawbacks associated with conventional formulations (such as systemic complications due to increased systemic API availability following chronic administration and adverse reactions induced by preservatives), novel strategies for ocular drug delivery are currently being researched and developed [1].

**Devices**

**Contact lenses**

Soft contact lenses can be used as drug delivery systems by immersing it in a solution of a given drug, as ocular tissue-drug contact time, flux across the cornea, as well as bioavailability increase, less
The eye only based on drug levels in and severe difficulty of insertion, the device ejection and -er 3 months to deliver potentially systems and despite a retention rate of 81%, a dose and bimatoprost containing punctual Pharmaceuticals, QLT Inc. (Vancouver, Canada) and Vistakon by approximately 2 mmHg nasolacrimal drainage system, as a decrease in IOP and thus the absorption of eye activities exist at present [2].

The contact lenses can be modified in order to immobilize drugs on their surface, as research shows and drugs can be entrapped using liposomes or micelles that are dispersed in the contact lens material, “smart” particles limiting drug release to the eye only based on factors such as pH or temperature in order to avoid drug loss during storage, as particle-laden contact lenses have been developed [1, 2, 5, 44, 45]. Gulsen et al. demonstrated the extended release of lidocaine from nanoparticle-loaded contact lenses over a period of 8 days [1, 5, 46, 47]. Molecular imprinted contact lenses have demonstrated higher drug loading capacity and provided sustained drug delivery regarding timolol [1, 5, 48]. Research is being developed for ion ligand-containing polymeric hydrogel and drug plate or drug solution combined piggyback contact lenses as well [2, 49, 50].

**Cul-de-sac inserts**

OcuSert® is a cul-de-sac insert that contains an internal layer of pilocarpine (an ocular hypotensive drug) in alginate gel within di-(ethylhexyl)phthalate as a release enhancer, between 2 external layers of ethylene-vinyl acetate copolymer and although in provides a uniform and controlled release (20 or 40 μg per hour for a week) of the active pharmaceutical ingredient, the difficulty of insertion, the device ejection and ocular irritation have limited its use due to the unsatisfactory control in intraocular pressure (IOP) [2, 51-53].

Lacrisert® is a water-soluble cul-de-sac hydroxypropyl cellulose insert developed for moderate and severe dry eye syndrome and although it does not contain preservatives, it has yet to be successfully applied [54].

The reluctance to abandon the traditional drug carrier systems and occasional device ejection have led to the commercial failure of these systems, as no further activities exist at present [2].

**Punctual plugs**

Punctual plugs are used to increase the retention time and thus the absorption of eye-drops, by blocking the nasolacrimal drainage system, as a decrease in IOP by approximately 2 mmHg was observed in plugged eyes compared to unplugged eyes following topical instillation of ocular hypotensive eye-drops [2, 55-57]. QLT Inc. (Vancouver, Canada) and Vistakon Pharmaceuticals, LLC have developed latanoprost and bimatoprost containing punctual plugs as delivery systems and despite a retention rate of 81%, a dose-response for IOP reduction has yet to be observed [2, 58].

**Episceral and subconjunctival implants**

LX201 is an episcleral implant composed of a a silicone matrix designed to continuously deliver potentially therapeutic cyclosporine levels to the lacrimal gland for a keratoconjunctivitis model in preclinical studies using rabbits and dogs [2, 59, 60].

3T Ophthalmics have developed a drug-filled silicone episcleral implant that provides high drug levels in the retina and posterior vitreous following scleral diffusion in animal studies, as clinical trials for retinoblastoma are planned [2, 61, 62].

Pfizer, Inc. has developed a subconjunctival insert composed of a poly (DL-lactide-co-glycolide) (PLGA) tube that contains a latanoprost-core. It releases its active pharmaceutical ingredient across the permeable end of the tube for a duration of 3 - 6 months. The release rate is regulated by the internal diameter of PLGA tube [2, 63].

**Microelectromechanical systems (MEMS)** are drug delivery devices made of parylene (biocompatible and flexible) that can be used by implanting their reservoir in the subconjunctival space, while a cannula is placed through an incision into the anterior or posterior segment of the eye. Electrolysis (driven by battery and wireless inductive power transfer) generates pressure inside the reservoir pushing the drug through the cannula, as water is transformed into hydrogen and oxygen gas due to the electrochemically-induced phase change. This allows a precise delivery of the desired dosage volume, overcoming the limits of the previous generation of manually-controlled MEMS consisting of variations regarding drug-release duration and force applied for depressing of the reservoir. MEMS device allows refilling with drug solution, providing long-term drug therapy which avoids repeated surgeries. Timolol or travoprost loaded MEMS have generated a continuous reduction in IOP for 8 hours in dogs, as no complications were observed after 3 months following subconjunctival device implantation with an anterior chamber placed canula. MEMS drug delivery devices are currently being investigated for the treatment regarding chronic and refractory ocular diseases, including glaucoma and age related macular degeneration (AMD) [2].

**Nanotechnology based ocular drug delivery systems**

**Liposomes**

A liposome is a vesicle composed of lipid layers (phospholipids, lipid conjugated polymers, and cholesterol) that entrap both lipophilic and hydrophilic drug molecules in an aqueous phase [64-66]. The fluidity of lipid bilayers (biodegradable in nature), surface charge (lipid dependent) and size are properties of liposomes that enhance corneal adhesion and drug penetration, especially when enhancing polymers and bio-adhesives are added to the formulation [64, 67].
In rabbit eyes, due to electrostatic interaction between the liposomes and the negatively charged corneal surface, the acyclovir concentration and absorption through cornea at two and a half hours following topical administration of cationic liposomes was higher than in the case of anionic liposomes and free acyclovir, as aqueous humor concentrations show [1, 68]. Chitosan coated coenzyme Q10 liposomes demonstrated an increase by almost 5 times regarding the precorneal residence time in the rabbit eye, proving the importance of mucoadhesive additives [1, 69].

Dong et al. used silk fibroin (a mucoadhesive material) coated, ibuprofen loaded liposomes to enhance drug retention and release time, as no toxicity was reported in human corneal epithelial cells [64, 70].

Huang et al. used a formulation based on betaxolol hydrochloride and montmorillonite for the treatment of glaucoma [64, 71].

Prostaglandins such as latanoprost have been used as stable liposomal formulations for ocular drug delivery in order to lower intraocular eye pressure in glaucoma via subconjunctival injection, while sodium hyaluronan, sodium hydroxide solution and sodium citrate were used as glycosaminoglycan- coated metallic nanoparticles via topical instillation to treat the dry eye [64, 72-75].

The administration of a rho-kinase inhibitor in association with latanoprost has led to increased treatment compliance and a further decrease in intraocular pressure (IOP) [76].

Tears again® is a spray that uses phospholipid liposomes in order to treat dry eye syndrome [1, 77, 78]. Liposomes provide sustained drug release by improving the vitreal half-life of drugs, protecting them from degradation and clearance, as studies conducted for fluconazole and tacrolimus show [1, 79-82].

Various effects associated with intravitreal instillation such as endophthalmitis, vitreous haemorrhage, and retinal detachment are minimized, as liposomes exert targeted drug delivery at the location of action and overcome the low bioavailability associated with topical instillation [64, 83].

Vallejo JC et al. used triamcinolone acetonide loaded liposomes for vitreous cavity and retina delivery in rabbit eyes, as no increase in intraocular pressure was observed [64, 84].

Li et al. demonstrated the sustainable drug release and low toxicity of a chitosan coated, triamcinolone acetonide loaded liposome used to treat macular oedema [64, 85].

Visudyne® uses verteporfin (a photosensitizer) loaded liposomes for photodynamic therapy regarding subfoveal choroidal neovascularization in AMD, presumed ocular histoplasmosis and pathological myopia [1, 86].

**Nanoparticles**

**Lipid nanoparticles.** Nanoparticles are drug loaded nanocapsules (drugs enclosed inside a polymeric shell) or nanospheres (drugs uniformly distributed throughout a polymeric matrix) composed of lipids, proteins, natural or synthetic polymers such as albumin, sodium alginate, chitosan, PLGA, polyactic acid (PLA) and polycaprolactone, ranging in size from ten to one thousand nanometres [1, 87-96]. Due to their small size and lipophilic nature, nanoparticles provide high ocular drug uptake by easily crossing barriers, with increased corneal absorption, providing high retention time and bioavailability at the ocular site, with sustained and targeted drug release that provide a high drug loading capacity and long term stability [64, 97-100]. They produce low toxicity and irritation levels due to their high biocompatibility and infrequent administration. They also provide sustained drug release based on particle size, large particles being less susceptible for rapid clearance and even providing transscleral delivery of the drug to the posterior tissues [1, 64, 101-104].

Furthermore, muco-adhesives such as chitosan, polyethylene glycol (PEG) and hyaluronic acid can be added in order to improve precorneal residence time, corneal permeation, bioavailability and drug release by overcoming the rapid elimination from the conjunctival pocket, as studies conducted on natamycin, melatonin and ofloxacin show [1, 64, 105-108].

Singh et al. used isoniazid loaded nanoparticles to demonstrate the high corneal permeation and retention of such formulas that provide a long drug half-life, as aqueous humor concentrations show [64, 109].

Ahmad and co-workers developed an etoposide loaded nanoparticle by melt-emulsification and ultrasonication technique with high penetration ability and entrapment efficiency that provided good drug concentration levels at the ocular site, maintaining the desired dose without any serious effect [64, 110].

Tatke and associates prepared triamcinolone acetonide loaded gellan gum combined nanoparticles by hot homogenization and ultrasonication technique for deep ocular tissue penetration [64, 111].

Some studies demonstrated sustained drug release following intravitreal injection of nanoparticles, as retinal pigmented epithelium and vitreous levels show, with negatively charged particles penetrating the entire retinal structures and reaching the external layers due to interaction between their anionic surface and the Müller cells as some drugs even reached the choroid through the disruption site of the retinal pigmented epithelium (RPE) and Bruch’s membrane in laser photocoagulated retinas, providing hope for the inhibition of choroidal neovascularization in age related macular degeneration [1, 112-115].

**Inorganic nanoparticles.** An inorganic nanoparticle is comprised of an inorganic core (such as quantum dots, gold, iron oxide or silica) and an organic (or metal) shell that protects the core in order to prevent drug degradation. The large surface area, high physical stability, great catalytic properties and intrinsic beneficial properties (such as antiangiogenic and anti-inflammatory properties in some cases) of these particles provide...
high compatibility and specificity in biological functions, as some ocular disorders (such as glaucoma, retinal diseases, age related macular degeneration, corneal fibrosis, retinoblastoma and ocular inflammation) have been well treated using inorganic nanoparticles as drug delivery systems [64, 116-118].

Li *et al.* used an amfenac-loaded polycatechin-capped gold nanoparticle that provided anti-inflammatory and anti-oxidative effects with no toxicity following drop instillation in dry eye treatment [64, 119].

Wang and co-workers proposed an N-acetyl carnosine loaded gold nanoparticle, obtained using *Coccinia grandis* bark extract for cataract treatment that provided high bioavailability and biocompatibility with no significant cytotoxic effect [64, 110].

Maulvi and co-workers combined timolol loaded gold nanoparticles with contact lenses in order to treat glaucoma, with results showing a considerable decrease in IOP levels due to increased drug delivery at the desired site following high uptake without swelling and optical transmittance problems of the contact lenses [64, 120].

Kim and co-workers developed a brimonidine loaded amino-functionalized mesoporous silica nanoparticle for the management of glaucoma that provided a substantial decrease in IOP due to an increase in drug residence time at the corneal site that led to high bioavailability following topical administration in the rabbit’s eye [64, 121, 122].

**Nano-micelles**

A polymeric micelle is a nanoscopic core covered by a shell structure formed by amphiphilic copolymers used to solubilize therapeutic agents into clear aqueous solutions. They are effective in transporting hydrophobic drugs and protein across biological membranes by enhancing drug stability, bioavailability and regulating drug release pattern. The high drug encapsulation capability, small size, ease of preparation and hydrophilic nano-micellar corona allow the drug to be retained in the systemic circulation for longer periods of time and accumulate at the location of the diseased tissue via enhanced permeation and retention (EPR) effect, with minimum non-specific accumulation of the drug in healthy tissues. Proper engineering techniques and selection of surfactant/polymer may aid in delivery of drugs to both posterior and anterior eye segments [1, 64, 123].

Civiale *et al.* used nano-micelles loaded with dexamethasone for anterior segment delivery demonstrating higher ocular drug bioavailability compared to dexamethasone suspension, as concentration time profiles following aqueous humor sampling in rabbits shows [1, 124].

Li and co-workers proved the high corneal permeation and anti-inflammatory properties of diclofenac loaded micelles in rabbit eyes, as no irritation was observed [64, 125].

Xu and his co-workers used nifedipine loaded PLA-PEG nano-micelles to constrain extracellular calcium ion influx as anticataract activity, as high drug biocompatibility and bioavailability were observed [64, 126]. Liaw *et al.* efficiently transferred plasmid DNA with pK12-Lac Z-PM gene for corneal delivery of keratin 12 and keratocan promoters by topical drug administration in mouse and rabbit eyes following endocytosis and particle size dependent paracellular transport of polymeric micelles [1, 127, 128].

Studies show that voclosporin, dexamethasone and rapamycin loaded nano-micelles were able to deliver therapeutic drug concentrations to posterior eye tissues post topical drug instillation, as their hydrophilic corona and small size helped them to evade the ocular barriers and produce low irritation and good tolerability [1, 129].

Ideta *et al.* used fluorescein isothiocyanate-labelled poly-L-lysine loaded nano-micelles via intravenous administration of the drug to treat neovascularization located in the posterior segment of the eye, as elevated retina-choroid drug concentration levels were detected up to 7 days following single administration [1, 130].

This high cytotoxic effect of dendritic photosensitizer (DP) loaded nano-micelles following light irradiation has been utilized for the photodynamic treatment of exudative AMD, as photocogulation was induced in rat eyes following intravenous injection and DP accumulation at the choroidal neovascular site [1, 131].

**Niosomes**

Niosomes are bi-layered, biodegradable and non-immunogenic vesicles of 10 nm to 0.1 µm composed of non-ionic surfactants that can carry both hydrophilic and lipophilic compounds in aqueous compartments. They have a long storage time (shelf-life), enhanced therapeutic effectiveness and reduced side effects due to their low systemic absorption [64, 85, 132]. Niosomes are available as drops for topical instillation used for treating ocular hypertension, dry eye, glaucoma, as well as eye infections. The enhanced precorneal retention time and drug absorption result in a sustained and prolonged discharge at the location of action, as inhibition of ocular metabolism in by lachrymal fluid and reduced systemic drainage provide an extended duration of action [64, 133].

Allam and co-workers demonstrated the enhanced antibacterial activity of a vancomycin niosomal gel against MRSA in rabbits [64, 134].

Nabarawi with his co-workers developed natamycin (NAT) loaded niosomes in ketorolac tromethamine (KT) gels with increased penetration rates and enhanced effectiveness against fungal keratitis following topical administration, as accelerated photoactivated chromophore collagen cross-linking could be a solution for infectious keratitis or corneal ulcer resistant to antimicrobial and antifungal therapy [64, 135, 136].

**Dendrimers**

A dendrimer is a branched, nanosized and star shaped polymeric drug carrier system available in many
different molecular weights with different terminal end functional groups that can incorporate both hydrophobic and hydrophilic drugs [1, 137-140]. Vandamme et al. demonstrated the increased ocular residence time, enhanced ocular bioavailability and better therapeutic outcomes of Poly (amidoamine) (PAMAM) dendrimers as an ophthalmic vehicle for drug delivery, as higher miotic and mydriatic activity in Albino rabbits was observed after co-administration of PAMAM dendrimers with pilocarpine nitrate and tropicamide [1, 138, 141]. The subconjunctival administration of glucosamine and glucosamine 6-sulfate loaded dendrimers in rabbit model eyes of filtration surgery regarding glaucoma have demonstrated significant inhibition of pro-angiogenic and pro-inflammatory responses with reduced formation of scar tissue [1, 142].

**Hydro-gels**

Hydrogels are polymeric, cross-linked solutions and undergo sol-gel phase transition induced by UV irradiation or changes in ions, temperature and pH and to form viscoelastic gels. For ocular delivery, thermosensitive polymers are mixed with drugs to form micellar aggregates that are temperature dependent and gelify at physiological temperature due to packing or aggregation [1, 64, 143-145]. The sustained drug release, prolonged corneal drug contact time, infrequent need of applications, decreased side effects and high ocular bioavailability suggest that thermosensitive gels could be a promising option for drug delivery regarding chronic ocular diseases [1]. Thermosensitive hydro-gels have been shown to produce higher drug concentration levels in the anterior chamber relative to eye drops, as studies based on dexamethasone loaded PLGA-PEG-PLGA (poly-(DL-lactic acid co-glycolic acid)-polyethylene glycol-poly-(DL-lactic acid co-glycolic acid)) polymers in rabbit model eyes demonstrate [1, 146]. Rieke et al. have reported the sustained drug release of an ovalbumin loaded biodegradable and thermosensitive triblock copolymer to the choroid and retina in the rat eye following subconjunctival administration [1, 147]. Liu and co-workers used a poly(ethylene glycol)-co-(1-lactic acid) diacrylate/N-isopropyl acrylamide (PEG-PLLA-DA/NIPAA) thermosensitive biodegradable hydrogel to deliver aflibercept in order to treat ocular neovascularization in a precise, safe and also effective manner [64, 148].

**Nanosuspensions**

Nanosuspensions are heterogeneous colloidal systems (10 to 1000 nm in size) stabilized by surfactants and used as carriers for hydrophobic drugs with poor solubility in lacrimal fluids [64, 149-151]. Their increased precorneal resistance time and enhanced ocular bioavailability are some advantages, as they easily cross ocular barriers (due to their size) and produce less irritation [1, 152]. Efforts have already been made towards improving ocular parameters such as bioavailability of glucocorticoids by formulating them as nanosuspensions, as current use of these drugs requires frequent administration at high doses which induce the formation of cataract and optic nerve damage [1, 153, 154]. Güven and co-workers have demonstrated the high entrapment efficiency, high drug loading percentage and persistent drug release of an olopatadine hydrochloride loaded nanosuspension used for treating allergic eye disease [64, 155]. Verma and co-workers designed an itraconazole loaded chitosan nanosuspension with good permeation, increased aqueous saturation solubility and effective in vitro discharge of the drug in the goat’s cornea [64, 156].

**Nanoemulsions**

A nanoemulsion is a colloidal dispersion found to possess kinetic and thermal stability. The interaction with the lipid layer of the tear film enhances the ocular residence time, as sustained drug release is provided due to high corneal permeation and penetration [64, 157-159]. Mahboobian and co-workers demonstrated the high corneal penetrating properties of a brinzolamide loaded nanoemulsion for the treatment of glaucoma [64, 160]. Shah et al. tested the bioavailability of a moxifloxacin loaded nano-emulsion, as high concentration levels at the target site were reported, with therapeutic effects being produced even at low dosing levels [64, 161].

**Implants**

Intraocular implants are injected into the vitreous via pars plana incision in order to provide a localized, controlled and sustained drug release over an extended period of time, with reduced side effects and enhanced ability to circumvent the blood retina barrier [1, 162-164]. Non-biodegradable implants are able to release the drug for extended periods of time due to their release kinetics and are made of ethylene vinyl acetate (EVA), polyvinyl alcohol (PVA) and polysulfone capillary fibre (PCF) polymers [1, 162, 164]. They require surgical removal after drug depletion and complications such as endophthalmitis, pseudo-endophthalmitis, vitreous haze, vitreous haemorrhage, cataract development and retinal detachment have limited their applications [1]. Biodegradable implants provide sustained drug release, are highly biocompatible and do not require surgical removal. They are made of PLA, polyglycolic acid (PGA), PLGA, and polycapro lactones polymers [1, 162]. Vitrasert® is an intraocular non-biodegradable implant composed of a 4.5 mg tablet of ganciclovir surrounded by EVA/PVA that slowly and passively releases the drug by diffusion through a small opening in EVA at the base of the device over a period of five to eight months, without systemic toxicity in order to treat cytomegalovirus retinitis [1, 2, 162, 164-167].
Retisert® is a non-biodegradable silicone laminated PVA implant approved by the FDA (Food and Drug Administration) for the treatment of chronic uveitis, as it provides the sustained release of fluocinolone acetonide for up to three years and although it effectively controls inflammation, reduces uveitis recurrences and improves visual acuity, cataract formation and elevated IOP have limited its application [1, 164, 165, 168, 169]. Iluvien® is a non-biodegradable, fluocinolone acetonide loaded, rod-shaped intravitreal implant made of polyimide and PVA developed in order to treat diabetic macular oedema (DME) that provides sustained drug delivery for up to three years, as higher percentages of patients whose visual acuity improved by at least 15 letters at 24 months were noted when compared to the control groups, some clinical trials show [2, 170, 171]. Dry age-related macular degeneration (AMD), wet AMD and macular oedema secondary to retinal vein occlusion (RVO) could also benefit from the application of Iluvien® [2, 172-174].

I-vation™ is a triamcinolone acetonide loaded, non-biodegradable titanium intravitreal implant coated with poly(methyl-methacrylate) and EVA predicted to provide sustained drug delivery for at least two years, as clinical trials regarding patients with DME that demonstrate an improvement in visual acuity and a decrease in macular thickness are currently being conducted [2, 175, 176].

Ozurdex® is an FDA approved biodegradable implant comprised of a PLGA polymer matrix that provides the release of dexamethasone for up to six months, as an improvement in visual acuity regarding macular oedema (caused by with either central or branch retinal vein occlusion), diabetic retinopathy. Irvine-Gass syndrome and posterior non-infectious uveitis was noted [1, 2, 164, 177].

Brimonidine tartrate loaded PLGA intravitreal biodegradable implants are being tested in phase II clinical studies regarding dry AMD and also phase I/II clinical trials regarding Retinitis Pigmentosa by Allergan, Inc., as the neurotrophins (including the ciliary neurotrophic factor and the brain-derived neurotrophic factor) released by this α2 adrenergic agonist have the potential to prevent the apoptosis of photoreceptors and/or RPE [2, 178-183].

Injectable Particulate Systems

Using Verisome™ (a translucent liquid) technology as a drug delivery platform, Icon Bioscience, Inc. have developed a triamcinolone acetonide loaded solution (IBI-20089), that becomes a milky, slightly opaque gel when mixed with saline. It is administered as an intravitreal injection in biodegradable benzyl benzoate and supposed to last for up to 1 year, as phase I studies for cystoid macular oedema associated with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) demonstrate a decrease in mean central subfield optical coherence tomography (OCT) thickness, with the substance being tested alongside ranibizumab for neovascular AMD [2, 184-186]. Cardillo et al. demonstrated the superior long-term pharmacologic performance of intravitreal injected triamcinolone acetonide loaded PLGA microspheres compared to naked triamcinolone acetonide injected eyes regarding patients with diffuse DME, as a marked decrease of the retinal thickness as well as an improvement in visual acuity were observed, as no complications were noted [2, 187]. Corticjet® is a dexamethasone palmitate (a corticosteroid prodrug) loaded preservative-free emulsion. It is composed of an oily carrier and a phospholipid as a surfactant that provides a sustained drug release of over 6 - 9 months, as the dexamethasone palmitate undergoes de-esterification and activation following intravitreal injection, with phase I studies for DME being conducted [2, 188, 189].

Visudyne® is a verteporfin (a photosensitizer) loaded intravenous liposomal formulation proposed for photodynamic therapy regarding presumed ocular histoplasmosis, pathological myopia or subfoveal choroidal neovascularization secondary to wet AMD [2, 190]. The encapsulated verteporfin accumulates in the vascular endothelial cells or into tumour cells via low density lipoprotein (LDL) receptor-mediated endocytosis, as phosphatidylglycerol (a negatively charged phospholipid) is a major constituent of Visudyne® formulation [2, 191]. Free verteporfin uptakes in neovascular tissues or in tumour cells after release in the blood flow from liposomes and associates with plasma LDL [2, 192].

Microneedles

Using microneedles, drugs can be deposited into the sclera or the suprachoroidal space, as diffusion into deeper ocular tissues such as choroid and retina may provide therapeutic effects for diseases such as AMD, diabetic retinopathy and posterior uveitis. This minimally invasive technique reduces the risks and complications associated with intravitreal injections, as microneedles only penetrate the superficial sclera, avoiding damage to the retina, vitreous, or choroid [1, 193].

Jason et al. demonstrated the high drug deposition of sulforhodamine coated microneedles following scleral injection in cadaver eyes [1, 194]. Jiang et al. [195] and Patel et al. [196] made attempts to infuse drug solutions, microparticles and nanoparticles into the sclera and the suprachoroidal space of human cadaver eyes and although results demonstrated the safeness and sustained drug release of the strategy, drugs may not reach the inner retinal tissues [1].

Iontophoresis

During iontophoresis, a weak direct current that drives charged molecules across the sclera is applied in order to deliver the drug into the vitreous, retina and choroid. The procedure requires an electrode to be placed elsewhere on the body in order to complete the
circuit. It is non-invasive in nature and avoids the risks and complications associated with surgical implantation or intravitreal injections [2]. In the rabbit, corneal dexamethasone levels were up to 30 fold higher following a single transcorneal iontophoresis for one minute (1 mA) in comparison to topical eye-drop instillation [2, 197]. EGP–437 is a dexamethasone phosphate compound currently undergoing clinical trials for the treatment of dry eye syndrome and anterior uveitis [2, 198-200].

Conclusions
While the reluctance to abandon the traditional drug carrier systems and occasional device ejection have led to the commercial failure of some systems, others have demonstrated to provide a localized, controlled and sustained drug release over an extended period of time, with reduced side effects and enhanced bioavailability.

Drug loaded nanoparticles have demonstrated to increase retention time, permeation and ocular bioavailability and seem to provide the increase retention time, permeation and ocular bioavailability enough to overcome the drawbacks associated with conventional eye-drops, while implants are proving to be promising for the posterior tissues. Nonetheless, more studies need to be conducted in order for the novel drug delivery systems to be established as a definite first choice option.

Conflict of interest
The authors declare no conflict of interest.

References
1. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol., 2013; 2(2): 47-64.
2. Kuno N, Fujii S. Recent Advances in Ocular Drug Delivery Systems. Polyomers, 2011; 3(1): 193-221.
3. Maurice DM, Mishima S. Ocular pharmacokinetics. In Pharmacology of the eye. Sears ML, Eds.; Springer: Heidelberg, Germany, 2012; 19-116.
4. Schoenwald RD. Ocular drug delivery. Clin Pharmacokinet., 1990; 18(4): 255-269.
5. Souto EB, Dias-Ferreira J, López-Machado A, Ettcheto M, Cano A, Camins Espunya A, Espina M, Garcia ML, Sánchez-López E. Advanced formulation approaches for ocular drug delivery: State-Of-The-Art and Recent Patents. Pharmaceutica, 2019; 11(9): 460: 1-29.
6. Abdelkader H, Fathalla Z, Moharram H, Ali TFS, Pierscionek B, Cycloexodrin Enhances Corneal Tolerability and Reduces Ocular Toxicity Caused by Diclofenac. Oxid Med Cell Longev., 2018; 2018: 5260976: 1-13.
7. Kesavan K, Kant S, Singh PN, Pandit JK. Effect of hydroxypropyl-beta-cycloexodrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel. Curr Eye Res., 2011; 36(10): 918-929.
8. Loftsson T, Stefánsson E. Cycloexodrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand., 2002; 80(2): 144-150.
9. Kurz D, Ciuilla TA. Novel approaches for retinal drug delivery. Ophthalmol Clin North Am., 2002; 15(3): 405-410.
10. Dubald M, Bourgeois S, Andrieu V, Fessi H. Ophthalmic drug delivery systems for antibiotherapy – A Review. Pharmaceutica, 2018; 10(1): 10: 1-31.
11. Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv., 2012; 2012; 604204: 1-16.
12. Vandamme TF, Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res., 2002; 21(1): 15-34.
13. Liang H, Brignole-Baudouin F, Rabinovich-Guillett L, Mao Z, Riano L, Faure MO, Warnet JM, Lambert G, Baudouin C. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis., 2008; 14: 204-216.
14. Opitz DL, Hanthan JS. Review of Azithromycin Ophthalmic 1% Solution (Azasite®) for the Treatment of Ocular Infections. Ophthalmol Eye Dis., 2012; 4: 1-14.
15. Ousler GW, Michaelson C, Christensen MT. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea, 2007; 26(8): 949-952.
16. Ursea R, Purcell TL, Tan BU, Nalgiarik A, Lovatan ME, Ehrenhaus MR, Schanzlin DJ. The effect of cyclosporine A (Restasis) on recovery of visual acuity following LASIK. J Refract Surg., 2008; 24(5): 473-476.
17. Tajika T, Isowaki A, Sakaki H, Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther., 2011; 27(1): 43-49.
18. Liu Y, Lin X, Tang X. Lipid emulsions as a potential delivery system for ocular use of azithromycin. Drug Dev Ind Pharm., 2009; 35(7): 887-896.
19. Shen J, Gan L, Zhu C, Zhang X, Dong Y, Jiang M, Zhu J, Gan Y. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. Int J Pharm., 2011; 412(1-2): 115-122.
20. Yamaguchi M, Ueda K, Isowaki A, Ohtori A, Takeuchi H, Ohguro N, Tojo K. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol Pharm Bull., 2009; 32(7): 1267-1271.
21. Irimia T, Muşat GC, Prisada RM, Ghica MV, Dinu-Pirvu CE, Anuţa V, Velescu BS, Popa L. Contributions on formulation and preliminary evaluation of ocular colloidal systems of chitosan and poloxamer 407 with bupivacaine hydrochloride. Farmacia, 2019; 67(4): 702-708.
22. Czajkowska-Kosnik A, Sznitowska M. Solubility of ocular therapeutic agents in self-emulsifying oils. I. Self-emulsifying oils for ocular drug delivery: Solubility of indomethacin, aciclovir and hydrocortisone. Acta Pol Pharm., 2009; 66(6): 709-713.
23. Robin JS, Ellis PP. Ophthalmic ointments. Surv Ophthalmol., 1978; 22(5): 335-340.
24. Scroggs J, Wallace T, Hanna C. Route of absorption of drug and ointment after application to the eye. Ann Ophthalmol., 1978; 10(3): 267-271.
25. MacKeen DL. Aqueous formulations and ointments. Int Ophthalmol Clin., 1980; 20(3): 79-92.
26. Rus LM, Donici E, Valica V, Prisacari V, Tomuță I, Şepeli D, Hegheș SC, Iuga CA, Uncu L. Development, physical-chemical characterization and in vitro antibacterial activity evaluation of a fixed-dose combination isohydrafural-methyluracil hydrophilic ointment. Farmacia, 2019; 67(5): 857-865.
27. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst., 1999; 16(1): 85-146.
28. Fukuda M, Hanazome I, Sasaki A. The intraocular dynamics of vancomycin hydrochloride ophthalmic ointment (TN-011) in rabbits. J Infect Chemother., 2003; 9(1): 93-96.
29. Occhiutto ML, Freitas FR, Maranhao RC, Costa VP. Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems. Pharmaceutics, 2012; 4(2): 252-275.
30. Eguchi H, Shiota H, Oguro S, Kasama T. The inhibitory effect of vancomycin ointment on the manifestation of MRSA keratitis in rabbits. J Infect Chemother., 2009; 15(5): 279-283.
31. Yasueda SI, Inada K, Matsuhashi K, Terayama H, Ohtori A. Evaluation of ophthalmic suspensions using surface tension. Eur J Pharm Biopharm., 2004; 57(2): 377-382.
32. Edman P. Pharmaceutical formulations -- Suspensions and solutions. J Aerosol Med., 1994; 7(Suppl 1): S3-S6.
33. Lang J, Roehrs R, Jani R. Ophthalmic preparations. In Remington: The Science and Practice of Pharmacy, 21st edition, Troy D, Eds.: Lippincott Williams & Wilkins: Philadelphia, USA, 2005: 856.
34. Scoper SV, Kabat AG, Owen GR, Stroman DW, Kabra BP, Faulkner R, Kulsreshtha AK, Rusk C, Bell B, Jamison T, Bernal-Perez LF, Brooks AC, Nguyen VA. Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraBac ST ophthalmic suspension. Adv Ther., 2008; 25(2): 77-88.
35. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol., 2013; 2(2): 47-64.
36. Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: A pharmacokinetic perspective. Clin Ophthalmol., 2016; 10: 2433-2441.
37. Andrew R, Ruecke G, Dozier S, Diven DG, A Pilot Study to Investigate the Efficacy of Tobramycin–Dexanethasone Ointment in Promoting Wound Healing. Dermatol Ther (Heidelb.), 2012; 2(1): 12: 1-6.
38. Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv., 2016; 23(8): 3017-3026.
39. Hsu KH, Guase S, Chauhan A. Review of ophthalmic drug delivery by contact lenses. J Drug Deliv Sci Technol., 2014; 24(2): 123-135.
40. Nasr FH, Khooe S, Dehghani MM, Chaleshtori SS, Shafiei A, Preparation and Evaluation of Contact Lenses Embedded with Polyacrolactone-Based Nanoparticles for Ocular Drug Delivery. Biomacromolecules, 2016; 17(2): 485-495.
41. ClinicalTrials.gov. Evaluation of efficacy and safety of an anti-allergy drug with a contact lens in allergic conjunctivitis. http://clinicaltrials.gov/ct2/show/NCT00432757?term=vistakon+AND+contact+lens&ran k=6.
42. ClinicalTrials.gov. Evaluation of efficacy and safety of an anti-allergy drug with a contact lens in the treatment of allergic conjunctivitis. http://clinicaltrials.gov/ct2/show/NCT00445874?term=vistakon+AND+contact+lens&rank=7.
43. Kim J, Chauhan A. Dexemethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels. Int J Pharm., 2008; 353(1-2): 205-222.
44. Sato T, Uchida R, Tanigawa H, Uno K, Murakami A. Application of polymer gels containing side-chain phosphate groups to drug-delivery contact lenses. J Appl Polym Sci., 2005; 98(2): 731-735.
45. Danion A, Brochu H, Martin Y, Vermette P. Fabrication and characterization of contact lenses bearing surface-immobilized layers of intact liposomes. J Biomed Mater Res A., 2007; 82(1): 41-51.
46. Gulsen D, Li CC, Chauhan A. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. Curr Eye Res., 2005; 30(12): 1071-1080.
47. Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. Int J Pharm., 2005; 292(1-2): 95-117.
48. Hiratani H, Fujisawa A, Tamiya Y, Mizutani Y, Alvarez-Lorenzo C. Ocular release of timolol from molecularly imprinted soft contact lenses. Biomaterials, 2005; 26(11): 1293-1298.
49. Sano K, Tokoro T, Imai Y. A new drug delivery system utilizing piggyback contact lenses. Acta Ophthalmol Scand., 1996; 74(3): 243-248.
50. Uchida R, Sato T, Tanigawa H, Uno K. Azulene incorporation and release by hydrogel containing methacyrylamide propyltrimethylammonium chloride, and its application to soft contact lens. J Control Release, 2003; 92(3): 259-264.
51. Macoul KL, Pavan-Langston D. Pilocarpine ocusert system for sustained control of ocular hypertension. Arch Ophthalmol., 1975; 93(8): 587-590.
52. Saettoni MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Del Rev., 1995; 16(1): 95-106.
53. Sihvola P, Puustjärvi T. Practical problems in the use of Ocusert-pilocarpine delivery system. Acta Ophthalmol (Copenh.), 1980; 58: 933-937.
54. Aton Pharma Inc. Lacrisert® (Hydroxypropylcellulose ophthalmic insert). www.lacrisert.com/ECP/pdfs/ClinicalTrials.gov. Evaluation of efficacy and safety of an anti-allergy drug with a contact lens in allergic conjunctivitis. Am J Ophthalmol., 1989; 107(2): 151-155.
55. Ariturk N, Oge I, Erkan D, Sulu Y, Sahin M. The effects of nasolacrimal canal blockage on topical medications for glaucoma. Am J Ophthalmol., 1996; 74(4): 411-413.
56. Bartlett JD, Boan K, Corliss D, Gaddie IB. Efficacy of silicone punctal plugs as adjuncts to topical pharmacotherapy of glaucoma — a pilot study. Punctal Plugs in Glaucoma Study Group. J Am Optom Assoc., 1996; 67(11): 664-668.
58. QLT Inc QLT announces phase II clinical trial results and development plans for the punctal plug delivery system. www.qltinc.com/newsCenter/documents/100310.

59. Kim H, Csaky KG, Gilger BC, Dunn JP, Lee SS, Tremblay M, de Monasterio F, Tansey G, Yuan P, Bungay PM, Lutz RJ, Robinson MR, Preclinical evaluation of a novel episcopal cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci, 2005; 46(2): 655-662.

60. Gilger BC, Moore CP, Narfstrom K, Liu J, Lawson C, Caeck T, Angliade E, Velgaleti P, Preclinical acute toxicity and pharmacokinetics of episcopal LX201 implants in rabbits. Invest Ophth Vis Sci, 2008; 49(13): 1964.

61. EuroTimes Episcleral implants could make eye injections obsolete. www.eurotimes.org/09November/episcleralimplants.pdf.

62. Pontes de Carvalho RA, Krausse ML, Murphree AL, Schmitt EE, Campochiaro PA, Maumenee IH, Delivery from episcleral exopants. Invest Ophth Vis Sci, 2006; 47(10): 4532-4539.

63. ClinicalTrials.gov. Safety study of latanoprost slow release insert (Latanoprost SR). http://clinicaltrials.gov/ct2/show/NCT01180062.

64. Qamar Z, Qizilbash FF, Iqbal MK, Ali A, Narang JK, Ali J, Baboota S, Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective. Recent Pat Drug Deliv Formul, 2019; 13(4): 246-254.

65. Bhattacharjee A, Das PJ, Adhikari P, Marbaniang D, Pal P, Ray S, Mazumder B, Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery. Eur J Ophthalmol., 2019; 29(1): 113-126.

66. Yadav KS, Rajpuruth R, Sharma S, Glaucoma: Current treatment and impact of advanced drug delivery systems. Life Sci., 2019; 221: 362-376.

67. Mishra GP, Bagui M, Tamboli V, Mitra AK, Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv., 2011; 2011: 863734: 1-14.

68. Law SL, Huang KJ, Chiang CH, Ayclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release, 2000; 63(1-2): 135-140.

69. Zhang J, Wang S, Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, preconical retention and anti-cataract effect. Int J Pharm., 2009; 372(1-2): 66-75.

70. Dong Y, Dong P, Huang D, Mei L, Xia Y, Wang Z, Pan X, Li G, Fabrication and characterization of silk fibroin-coated liposomes for ocular drug delivery. Eur J Pharm Biopharm., 2015; 91: 82-90.

71. Huang Y, Tao Q, Hou D, Hu S, Tian S, Chen Y, Gui R, Yang L, Wang Y, A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride. Int J Nanomedicine, 2017; 12: 1731-1745.

72. Venkatraman S, Natarajan JV, Howden T, Boey F, Stable liposomal formulations for ocular drug delivery. US9/556,195., 2018.

73. Venkatraman S, Natarajan JV, Wong T, Boey YC, Liposomal formulation for ocular drug delivery. US10/272,040., 2019.

74. Venkatraman S, Joseph RR, Boey YC, Subconjunctival depot forming formulations for ocular drug delivery. US16/095,269., 2019.

75. Fullwood NJ, Glycosaminoglycan-coated metallic nanoparticles and uses thereof. US15/560,972., 2018.

76. Iancu R, Pirvulescu R, Istrate S, Popa-Cherecheanu A, Iancu G, Burcea M, Rho-kinase inhibitors – a new broad-spectrum treatment in ophthalmic diseases. A review. Farmacia, 2021; 69(3): 399-409.

77. Dausch D, Lee S, Dausch S, Kim JC, Schwert G, Michelson W. Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes. Klin Monbl Augenheilkd, 2006; 223(12): 974-983, (available in German).

78. Lee S, Dausch S, Maiherhofer G, Dausch D. A new therapy concept for the treatment of dry eye—the usefulness of phospholipid liposomes. Klin Monbl Augenheilkd, 2004; 221(10): 825-836, (available in German).

79. Bochot A, Fattal E, Liposomes for intravitreal drug delivery: a state of the art. J Control Release, 2012; 161(2): 628-634.

80. Alghadyan AA, Peyman GA, Khoobbeli B, Milner S, Liu KR, Liposome-bound cyclosporine: clearance after intravitreal injection. Int Ophthalmol., 1988; 12(2): 109-112.

81. Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluonazole in rabbit eyes. J Ocul Pharmacol Ther., 2000; 16(6): 511-518.

82. Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci., 2010; 51(7): 3575-3582.

83. Gerossi DH, Edelhauser HF, Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci., 2000; 41(5): 961-964.

84. Altamirano-Vallejo JC, Navarro-Partida J, Gonzalez-De la Rosa A, Hsiao IH, Olguin-Gutierrez JS, Gonzalez-Villegas AC, Keller BC, Bouzo-Lopez L, Santos A. Characterization and pharmacokinetics of triamcinolone acetonide-loaded liposomes topical formulations for vitreoretinal drug delivery. J Ocul Pharmacol Ther., 2018; 34(5): 416-425.

85. Sahoo SK, Dilnavaz F, Krishnakumar S, Nanotechnolgy in ocular drug delivery. Drug Discov Today, 2008; 13(3-4): 144-151.

86. Keam SJ, Scott LJ, Curran MP, Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs, 2003; 63(22): 2521-2554.

87. Hirjäuu M, Miron DS, Anuţa V, Lupuiliasa D, Ghica MV, Jinga V, Dinha-Pirvu CE, Evaluation of Experimental Multi-Particulate Polymer-Coated Drug Delivery Systems with Meloxicam. Coatings, 2020; 10(5): 490: 1-22.

88. Nagarwal RC, Kumar R, Pandit JK, Chitosan coated sodium alginates-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci., 2012; 47(4): 678-685.

89. Gupta H, Aql M, Khar RK, Ali A, Bhatnagar A, Mittal G, Sparfloxacin-loaded PLGA nanoparticles
for sustained ocular drug delivery. Nanomedicine, 2010; 6(2): 324-333.

90. Singh KH, Shinde UA, Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate. Curr Drug Deliv., 2010; 7(3): 244-251.

91. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G, Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target., 2011; 19(6): 409-417.

92. Agnihotri SM, Vavia PR, Diolofenac-loaded biopolymeric nanoparticles for opthalmic application. Nanomedicine, 2009; 5(1): 90-95.

93. Nair KL, Vidyarany S, James J, Kumar GSV, Pillocarpine-loaded poly(DL-lactic-co-glycolic acid) nanoparticles as potential candidates for controlled drug delivery with enhanced ocular pharmacological response. J Appl Polym Sci., 2012; 124(3): 2030-2036.

94. Ibrahim HK, El-Leithy IS, Makky AA, Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy, Mol Pharm., 2010; 7(2): 576-585.

95. Pignatello R, Ricupero N, Bucolo C, Mauger F, Maltese A, Puglisi G, Preparation and characterization of Eudragit Retard nanoparticles for the ocular delivery of clorocerine. AAPS PharmSciTech., 2006; 7(1): E192-E198.

96. Bhagav P, Upadhyay H, Chandran S, Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech., 2011; 12(4): 1087-1101.

97. Seyfoddin A, Al-Kassas R, Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm., 2013; 39(4): 508-519.

98. Kaur IP, Kanwar M, Ocular preparations: the formulation approach. Drug Dev Ind Pharm., 2002; 28(5): 473-493.

99. Kaur IP, Rana C, Singh H, Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther., 2008; 24(5): 481-493.

100. Cavalli R, Gasco RM, Chetoni P, Burglassi S, Saettone MF, Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm., 2002; 238(1-2): 241-245.

101. Mukherjee S, Ray S, Thakur RS, Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci., 2009; 71(4): 349-358.

102. Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Dolatabadi JE, Omidfar K, Drug targeting using solid lipid nanoparticles. Chem Phys Lipids, 2014; 181: 56-61.

103. Amrite AC, Kompella UB, Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol., 2005; 57(12): 1555-1563.

104. Amrite AC, Edelhauser HF, Singh SR, Kompella UB, Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis., 2008; 14: 150-160.

105. Bu HZ, Guksayen HJ, Goulet L, Lou XJ, Xiang C, Koudriakova T, Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab., 2007; 8(2): 91-107.

106. Bhatta RS, Chandasana H, Chhonker YS, Rathi C, Kumar D, Mitra K, Shukla PK, Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. Int J Pharm., 2012; 432(1-2): 105-112.

107. Musumeci T, Bucolo C, Carbone C, Pignatello R, Drago F, Puglisi G, Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. Int J Pharm., 2013; 440(2): 135-140.

108. Eid HM, Elkomy MH, El Menshawie SF, Salem HF, Development, Optimization, and In vitro In vivo characterization of enhanced lipid nanoparticles for ocular delivery of oloftacin: The influence of pegylation and chitosan coating. AAPS PharmSciTech., 2019; 20(5): 183: 1-14.

109. Singh M, Guzman-Aranguez A, Hussain A, Srinivas CS, Kaur IP, Solid lipid nanoparticles for ocular delivery of Isoniazid: evaluation, proof of concept and in vivo safety & kinetics. Nanomedicine (Lond.), 2019; 14(4): 465-491.

110. Ahmad I, Pandit J, Sultana Y, Mishra AK, Hazari PP, Aqil M, Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. Mater Sci Eng C Mater Bioll Appl., 2019; 100: 959-970.

111. Tatke A, Dudhipala N, Janga KY, Balguri SP, Avula B, Jablonski MM, Majumdar S, In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: Tear kinetics and ocular disposition studies. Nanomaterials (Basel), 2018; 9(1): 33-1-17.

112. Zhang L, Li Y, Zhang C, Wang Y, Song C, Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. Int J Nanomedicine, 2009; 4: 175-183.

113. Bourges JL, Gautier SE, Delie F, Benjiani RA, Jeanny JC, Gurny R, BenErra D, Behar-Cohen FF, Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophth Vis Sci., 2003; 44(8): 3562-3569.

114. Koo H, Moon H, Han H, Na JH, Huh MS, Park JH, Wook SJ, Park KH, Kwon IC, Kim K, Kim H, The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials, 2012; 33(12): 3485-3493.

115. Kim H, Robinson SB, Casyk KG, Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res., 2009; 26(2): 329-337.

116. Pandey P, Dahiya M, A brief review on inorganic nanoparticles. J Crit Rev., 2016; 3(3): 18-26.

117. Mohammadpour R, Dobrovolskaia MA, Cheney DL, Greish KF, Ghandehari H, Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Deliv Rev., 2019; 144: 112-132.

118. Masse F, Ouellette M, Lamoureux G, Boisselier E, Gold nanoparticles in ophthalmology. Med Res Rev., 2019; 39(1): 302-327.

119. Li YJ, Luo LJ, Harroun SG, Wei SC, Unnikrishnan B, Chang HT, Huang YF, Lai JY, Huang CC, Synergistically dual-functional nano eye-drops for
120. Wang Y, Xia R, Hu H, Peng T. Biosynthesis, characterization and cytotoxicity of gold nanoparticles and their loading with N-acetylcarnosine for cataract treatment. *J Photochem Photobiol B.*, 2018; 187: 180-183.

121. Maulvi FA, Patil RJ, Desai AR, Shukla MR, Vaidya RJ, Ranch KM, Vyas BA, Shah SA, Shah DO. Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: *In vitro* and *in vivo* evaluation. *Acta Biomater.*, 2019; 86: 350-362.

122. Kim SN, Ko SA, Park CG, Lee SH, Huh BK, Park YH, Kim YK, Ha A, Park KH, Choy YB. Amino-functionalized mesoporous silica particles for ocular delivery of brimonidine. *Mol Pharm.*, 2018; 15(8): 3143-3152.

123. Özsöy Y, Güngör S, Kahraman E, Durgun ME, Yılmaz ZS, Yıldız N. Functionalized mesoporous silica particles for ocular drug delivery. *FEBS Lett.*, 2019; 593(13): 1838-1843.

124. Li M, Lan J, Li X, Xin M, Wang H, Zhang F, Lu X, Zhuang Z, Wu X. Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery. *Int J Pharm.*, 2009; 378(1-2): 177-186.

125. Liu W, Lee BS, Mieler WF, Kang JJ, Rieke ER, Amaral J, Becerra SP, Lutz RJ, Balta G, Zemba M, Branduse L, Mehedintu C, Burcea M, Barac AD, Branisteancu DC, Balta F, Vögtle F, Dendrimers: From Design to Application-A Progress Report. *Angew Chem Int Ed Engl.*, 1999; 38(7): 884-905.

126. Abdelkader H, Alany RG. Controlled and continuous release ocular drug delivery systems: pros and cons. *Curr Drug Deliv.*, 2012; 9(4): 421-430.

127. Pataro G, Malecza F, Turrin CO, Soler V, Duhayon C, Elena PP, Majoral JP, Caminade AM. Designing dendrimers for ocular drug delivery. *Eur J Med Chem.*, 2010; 45(1): 326-334.

128. Vandanne TF, Brobeck L. Poly(amideamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. *J Control Release*, 2005; 102(1): 23-38.

129. Shaunak S, Thomas S, Giansai E, Godwin A, Jones E, Teo I, Mireskandari K, Luthert P, Duncan R, Patterson S, Khaw P, Brocchini S. Polyaldehyde dendrimer glucosamine conjugates prevent scar tissue formation. *Nat Biotechnol.*, 2004; 22(8): 977-984.

130. Barar J, Aghanejad A, Fathi M, Omidi Y. Advanced drug delivery and targeting technologies for the ocular diseases. *Biosimilars*, 2016; 6(1): 49-67.

131. Rajgoria G, Gupta A. In-Situ Gelling System: A Novel Approach for Ocular Drug Delivery. *AJPTR.*, 2012; 2(4): 24-53.

132. Bonacucina G, Cespi M, Nencarelli G, Giorgioni P, Palmieri GF. Thermosensitive Self-Assembling Block Copolymers as Drug Delivery Systems. *Polymers*, 2011; 3(2): 779-811.

133. Gao Y, Sun Y, Ren F, Gao S, PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. *Drug Dev Ind Pharm.*, 2010; 36(4): 423-432.

134. Rieke ER, Amaral J, Becerra SP, Lutz RJ. Sustained subconjunctival protein delivery using a thermosetting gel delivery system. *J Ocul Pharmacol Ther.*, 2010; 26(1): 55-66.

135. Liu W, Lee BS, Mieler WF, Kang-Mieler JJ. Biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of bioactive aflibercept *in vitro*. *Curr Eye Res.*, 2019; 44(3): 264-274.

136. Wang X, Wang S, Zhang Y. Advance of the application of nano-controlled release system in ophthalmic drug delivery. *Drug Deliv.*, 2016; 23(8): 642-648.
metabolising enzymes and transporters. Expert Opin Drug Deliv., 2005; 2(5): 891-908.
151. Patel MH, Patel BU, Shah C, Akbari B, Formulation and development of nanosuspension as an alternative approach for solubility and dissolution enhancement of acyclovir. J Appl Pharm Sci., 2018; 7(5): 33-47.
152. Patravale VB, Date AA, Kulkarni RM, Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol., 2004; 56(7): 827-840.
153. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM, Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm., 2007; 340(1-2): 126-133.
154. Ali HSM, York P, Ali AMA, Blagden N, Hydrocoritzone nano-suspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. J Control Release, 2011; 149(2): 175-181.
155. Gäven UM, Yenilmez E, Olopatadine hydrochloride loaded Kollidon® SR nanoparticles for ocular delivery: Nanosuspension formulation and in vitro-in vivo evaluation. J Drug Deliv Sci Technol., 2019; 51: 506-512.
156. Ahuja M, Verma P, Bhatia M, Preparation and evaluation of chitosan–itraconazole co-precipitated nanosuspension for ocular delivery. J Exp Nanosci., 2015; 10(3): 209-221.
157. Anton N, Benoit JP, Saulnier P, Design and production of nanoparticles formulated from nano-emulsion templates—a review. J Control Release, 2008; 128(3): 185-199.
158. Ammar HO, Salama HA, Ghorab M, Mahmoud AA, Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery. Drug Dev Ind Pharm., 2010; 36(11): 1330-1339.
159. Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM, W/O microemulsions for ocular delivery: evaluation of ocular irritation and preconual retention. J Control Release, 2006; 111(1-2): 145-152.
160. Mahboobian MM, Seyfoddin A, Aboosefazeli R, Foroutan SM, Rupenthal ID, Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests. Pharm Dev Technol., 2019; 24(5): 600-606.
161. Shah J, Nair AB, Jacob S, Patel RK, Shah H, Shehata TM, Morsy MA, Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics., 2019; (11): 230: 1-16.
162. Bourges JL, Bloquel C, Thomas A, Frousart F, Bochot A, Azain F, Gurny R, Ben Ezra D, Behar-Cohen F, Intracameral implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev., 2006; 58(11): 1182-1202.
163. Del Amo EM, Urtti A, Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today, 2008; 13(3-4): 135-143.
164. Lee SS, Hughes P, Ross AD, Robinson MR, Biodegradable implants for sustained drug release in the eye. Pharm Res., 2010; 27(10): 2043-2053.
165. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, du Toit LC, A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci., 2010; 99(5): 2219-2239.
166. Bausch & Lomb Vittaret® (ganciclovir intravitreal implant) 4.5 mg. www.bausch.com/en_US/ecp/pharma/product/vittaret.aspx.
167. Bausch & Lomb Vitravene® Sterile Intravitreal Implant with Cytovene® (ganciclovir, 4.5 mg). www.bausch.com/en_US/package_insert/surgical/vitravene_.pdf.
168. Mohammad DA, Sweet BV, Elner SG, Retisert: is the new advance in treatment of uveitis a good one?. Ann Pharmacother., 2007; 41(3): 449-454.
169. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P, Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology, 2005; 112(7): 1192-1198.
170. Kane FE, Burdan J, Cutino A, Green KE, Iluvien: A new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv., 2008; 5(9): 1039-1046.
171. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F, Famous study Group, Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology, 2010; 117(7): 1393-1399.
172. ClinicalTrials.gov. The MAP Study: Fluocinolone acetonide (FA)/Medidur™ for age related macular degeneration (AMD) Pilot. http://clinicaltrials.gov/ct2/show/NCT00605423?term=Iluvien&rank=12.
173. ClinicalTrials.gov. Fluocinolone acetonide intravitreal inserts in geographic atrophy. http://clinicaltrials.gov/ct2/show/NCT00695318?term=Iluvien&rank=15.
174. ClinicalTrials.gov. Fluocinolone acetonide intravitreal inserts for vein occlusion in retina (FAVOR). http://clinicaltrials.gov/ct2/show/NCT00770770?term=Iluvien&rank=9.
175. SlnModics I-vation™ Sustained Drug Delivery System: Intravitreal Implant for Fung Delivery. www.slnmodics.com/pdf/opthalmology.pdf.
176. Dudgel PU, Eliot D, Cantrill HL, Mahmoud T, Avery R, Erickson SR, I-Vation™ TA: 24-month clinical results of the Phase I safety and preliminary efficacy study. Invest Ophth Vis Sci., 2009; 50(13): 4332: 1-7.
177. Allergan Allergan receives FDA approval for Ozurdex® as treatment option for non-infectious uveitis affecting the posterior segment of the eye. http://agn.client. shareholder.com/release/detail.cfm?ReleaseID=511060.
178. Longnres U, Napangangs U, Lafuente M, Mayor S, Lindqvist N, Vidal-Sanz M, Hallbook F, The growth factor response in ischemic rat retina and superior colliculus after bromidine pre-treatment. Brain Res Bull., 2006; 71(1-3): 208-218.
179. Kim HS, Chang YI, Kim JH, Park CK, Alteration of retinal intrinsic survival signal and effect of alpha2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat. Vis Neurosci., 2007; 24(2): 127-139.
180. Azadi S, Johnson LE, Paquet-Durand F, Perez MT, Zhang Y, Ekstrom PA, van Veen T, CNTF+BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res., 2007; 1129(1): 116-129.
181. Zhang M, Mo X, Fang Y, Guo W, Wu J, Zhang S, Huang Q, Rescue of photoreceptors by BDNF gene transfer using in vivo electroporation in the RCS rat of retinitis pigmentosa. *Curr Eye Res.*, 2009; 34(9): 791-799.

182. ClinicalTrials.gov. Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration (AMD). http://clinicaltrials.gov/ct2/show/NCT00658619.

183. ClinicalTrials.gov. An exploratory study to evaluate the safety of brimonidine intravitreal implant in patients with retinitis pigmentosa. http://clinicaltrials.gov/ct2/show/NCT00661479.

184. Wong V, Wood L, Conveniently Implantable Sustained Release Drug Compositions. U.S. Patent WO2006/039336., 2006.

185. Lim JI, Hung D, Fung AE, Wieland M, Wong V, One year results of a Phase 1 study evaluating the safety and evidence of efficacy of a single intravitreal injection of the Verisome™ liquid drug delivery system for sustained release of low-dose triamcinolone (IBI-20089) in eyes with cystoid macular edema. *Invest Ophth Vis Sci.*, 2010; 51(13): 6396: 1-7.

186. ClinicalTrials.gov. IBI 20089+Lucentis combo intravitreal injections for treatment of neovascular age-related macular degeneration (AMD) (Icon Combo). http://clinicaltrials.gov/ct2/show/NCT01175395?term=IBI20089&rank=1.

187. Cardillo JA, Souza-Filho AA, Oliveira AG, Intravitreal biorurdex sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulness for the treatment of diabetic macular edema. *Arch Soc Exp Oftalmol.*, 2006; 81(12): 675-677, 679-681.

188. Novagari Pharma SA Eyeject®. www.novagali.com/eyeject/.

189. ClinicalTrials.gov. Safety and tolerability of NOVA 63035 “Corticosteroid” in patients with diabetic macular edema secondary to diabetic retinopathy. http://clinicaltrials.gov/ct2/show/NCT00665106?term=NOVA63035&rank=1.

190. QLT Ophthalmics Visudyne®. www.visudyne.com/.

191. Amin K, Wasan KM, Albrecht RM, Heath TD, Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr. *J Pharm Sci.*, 2002; 91(5): 1233-1244.

192. Allison BA, Pritchard PH, Levy JG, Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. *Br J Cancer*, 1994; 69(5): 833-839.

193. Donnelly RF, Raj Singh TR, Woolson AD, Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. *Drug Deliv.*, 2010; 17(4): 187-207.

194. Jiang J, Gill HS, Ghide D, McCarey BE, Patel SR, Edelhauser HF, Pannuzzo MR, Coated microneedles for drug delivery to the eye. *Invest Ophth Vis Sci.*, 2007; 48(9): 4038-4043.

195. Jiang J, Moore JS, Edelhauser HF, Pannuzzo MR, Intracocular drug delivery to the eye using hollow microneedles. *Pharm Res.*, 2009; 26(2): 395-403.

196. Patel SR, Lin AS, Edelhauser HF, Pannuzzo MR, Suprachoroidal drug delivery to the back of the eye using hollow microneedles. *Pharm Res.*, 2011; 28(1): 166-176.

197. Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ, Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. *J Control Release*, 2005; 106(3): 386-390.

198. Eyegate Pharmaceuticals EyeGate Pharma Initiates ALLUVION Phase III Study of EGP-437 in Patients with Dry Eye Syndrome. www.eyegatepharma.com/pdf/news2010/EyegatePR_DES_Ph%20III_Final.pdf.

199. ClinicalTrials.gov. Safety and efficacy study of EGP-437 (Dexamethasone phosphate formulated for ocular iontophoresis) to treat dry eye. http://clinicaltrials.gov/ct2/show/NCT01129856?term=EyeGate&rank=3.

200. ClinicalTrials.gov. Safety and efficacy study of iontophoresis and dexamethasone phosphate to treat anterior uveitis. http://clinicaltrials.gov/ct2/show/NCT00694135?term=EyeGate&rank=4.